> Subject: NATAP/EASL: Tenofovir HBV/HCC Risk
>
> Long-term Tenofovir Disoproxil Fumarate (TDF) Therapy and the Risk of Hepatocellular Carcinoma
>
> - see attached full slide presentation
>
>
> Reported by Jules Levin
>
> EASL 2013 April 24-28 Amsterdam
>
>
>
> W. Ray Kim1, Thomas Berg2, Rohit Loomba3, Raul Aguilar Schall4, Phillip Dinh4, Leland J. Yee4, Eduardo Bruno Martins4, John F. Flaherty4, Selim Gurel5, Maria Buti6, Patrick Marcellin7
>
> 1Mayo Clinic, Rochester, MN, USA; 2Universitätsklinikum Leipzig, Germany; 3University of California at San Diego, USA; 4Gilead Sciences, Inc., Foster City, CA; 5University of Uludag, Bursa, Turkey; 6Hospital General Universitari Vall d’Hebron, Barcelona, Spain; 7Hôpital Beaujon, University of Paris, Clichy, France
>
> HCC is an important complication of CHB1
> Risk score algorithms have been developed to estimate risk of developing HCC2‒5
> The impact of therapy with oral antivirals, such as TDF, on the development of HCC has not been
> well characterized
>
> STUDY AIM
> To compare the observed incidence of HCC in patients treated with TDF in studies GS-US-174-0102 and GS-US-174-0103 with the predicted HCC incidence based on the REACH-B risk calculator
>
> Author’s SUMMARY
>
> The incidence of HCC in patients on TDF in studies GS-US-174-0102 and GS-US-174-0103 was lower than predicted by the REACH-B model
> In noncirrhotic patients, the effect of TDF becomes noticeable at approximately 2 years of therapy and became significant (55% reduction) at 6 years of therapy
> TDF effect was less pronounced in cirrhotic patients; however, the number of cirrhotics with HCC was small and may not rule out longer-term benefits
>
